LMAT icon

LeMaitre Vascular

83.69 USD
-2.06
2.40%
At close Jul 11, 4:00 PM EDT
After hours
83.69
+0.00
0.00%
1 day
-2.40%
5 days
-0.42%
1 month
0.66%
3 months
1.05%
6 months
-11.13%
Year to date
-8.51%
1 year
-1.58%
5 years
219.79%
10 years
644.57%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Employees: 664

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]

0.59% less ownership

Funds ownership: 94.16% [Q4 2024] → 93.57% (-0.59%) [Q1 2025]

7% less funds holding

Funds holding: 305 [Q4 2024] → 285 (-20) [Q1 2025]

9% less capital invested

Capital invested by funds: $1.95B [Q4 2024] → $1.77B (-$180M) [Q1 2025]

15% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 120

26% less call options, than puts

Call options by funds: $25K | Put options by funds: $34K

34% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 44

Research analyst outlook

We haven’t received any recent analyst ratings for LMAT.

Financial journalist opinion

Based on 3 articles about LMAT published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
Positive
Seeking Alpha
1 week ago
Don't Be Too Cute, Buy These 3 Dividend Growers Instead
We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a niche medical devices company, and Michigan's largest regulated utility. Relative to our fair value estimates, the trio of fast-growing businesses are trading at 4% to 7% discounts.
Don't Be Too Cute, Buy These 3 Dividend Growers Instead
Positive
Seeking Alpha
3 weeks ago
LeMaitre Vascular: Scaling Nicely As Global Demand Builds
LeMaitre's revenue and earnings continue to grow, though profit growth has moderated. The European launch of Artegraft and pending approval of XenoSure in China are key near-term catalysts. The portfolio's increasing share of biologic products combined with operational improvements are supporting high margins.
LeMaitre Vascular: Scaling Nicely As Global Demand Builds
Neutral
GlobeNewsWire
2 months ago
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV.
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
Neutral
Seeking Alpha
2 months ago
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
Neutral
GlobeNewsWire
2 months ago
LeMaitre Q1 2025 Financial Results
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
LeMaitre Q1 2025 Financial Results
Positive
Zacks Investment Research
3 months ago
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
Neutral
GlobeNewsWire
3 months ago
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
Neutral
Zacks Investment Research
3 months ago
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Charts implemented using Lightweight Charts™